DDInter1083 DDInter1676
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lofexidine {u} (Compound) resembles {v} (Compound) Apraclonidine
Lofexidine {u} (Compound) binds {v} (Gene) ADRA2A
Lofexidine {u} (Compound) upregulates {v} (Gene) HMGA2
Lofexidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Lofexidine (Compound) resembles Apraclonidine (Compound)
Lofexidine (Compound) binds ADRA2A (Gene)
Lofexidine (Compound) upregulates HMGA2 (Gene)
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Lofexidine may lead to a major life threatening interaction when taken with Ribociclib
Lofexidine may lead to a major life threatening interaction when taken with Toremifene